You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR MITOXANTRONE HYDROCHLORIDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for mitoxantrone hydrochloride

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002003 ↗	Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas	Completed	Lederle Laboratories	Phase 2	1969-12-31	To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
NCT00002259 ↗	Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma	Completed	Lederle Laboratories	Phase 2	1969-12-31	To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.
NCT00002474 ↗	Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer	Completed	Loyola University	Phase 2	1991-02-01	RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with autologous bone marrow transplant may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy and autologous bone marrow transplant work in treating patients with refractory or recurrent ovarian cancer.
NCT00002498 ↗	Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer	Unknown status	Leiden University Medical Center	Phase 2	1992-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different combinations may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of cyclophosphamide, methotrexate, and fluorouracil with mitoxantrone in treating older patients with recurrent or metastatic breast cancer.
NCT00002514 ↗	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	Completed	Medical Research Council	Phase 3	1993-04-01	RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for mitoxantrone hydrochloride

Condition Name

Chart
Table

Condition Name for mitoxantrone hydrochloride
Intervention	Trials
Leukemia	49
Acute Myeloid Leukemia	45
Prostate Cancer	29
Lymphoma	26
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for mitoxantrone hydrochloride
Intervention	Trials
Leukemia	181
Leukemia, Myeloid, Acute	134
Leukemia, Myeloid	133
Lymphoma	78
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for mitoxantrone hydrochloride

Trials by Country

Map
Table

Trials by Country for mitoxantrone hydrochloride
Location	Trials
Canada	140
China	86
Germany	64
Spain	56
Australia	56
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for mitoxantrone hydrochloride
Location	Trials
California	62
New York	55
Ohio	49
Illinois	49
Texas	47
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for mitoxantrone hydrochloride

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for mitoxantrone hydrochloride
Clinical Trial Phase	Trials
Phase 4	13
Phase 3	82
Phase 2/Phase 3	4
[disabled in preview]	194
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for mitoxantrone hydrochloride
Clinical Trial Phase	Trials
Completed	181
Recruiting	47
Terminated	46
[disabled in preview]	81
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for mitoxantrone hydrochloride

Sponsor Name

Chart
Table

Sponsor Name for mitoxantrone hydrochloride
Sponsor	Trials
National Cancer Institute (NCI)	74
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	27
Fred Hutchinson Cancer Research Center	12
[disabled in preview]	18
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for mitoxantrone hydrochloride
Sponsor	Trials
Other	414
Industry	182
NIH	75
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.